ASCO Congratulates Stephen M. Hahn, MD, FASTRO, on Nomination to Serve as FDA Commissioner

Statement by Howard A. “Skip” Burris III, MD, FACP, FASCO
November 1, 2019

“The American Society of Clinical Oncology (ASCO) congratulates Stephen M. Hahn, MD, FASTRO, on his nomination by President Trump to serve as the next Commissioner of the Food and Drug Administration (FDA). An oncologist and long-time member of ASCO, Dr. Hahn currently serves as the Chief Medical Executive at The University of Texas MD Anderson Cancer Center. He has a strong grasp of the drug development process and understands the realities of working in a complex clinical care environment at one of the largest cancer centers in the world. 

“The role of FDA Commissioner requires a strong commitment to advancing the agency’s mission to protect public health across the United States, and an understanding of how to help speed innovations to get new treatments to patients, while also ensuring the safety and efficacy of the medical products that millions of Americans rely on to manage, treat, and cure their cancer. 

“ASCO has a long and productive history of collaborating with FDA, including with current acting Commissioner Norman E. “Ned” Sharpless, MD, in support of the agency’s important role in reducing cancer incidence, advancing treatment options, and improving the lives of individuals with cancer. We look forward to continuing our close collaboration to make it possible for every American with cancer to have access to medical products that are safe and effective.”

ASCO in Action